These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11522012)

  • 1. High affinity binding of heparin by necrotic tumour cells neutralises anticoagulant activity--implications for cancer related thromboembolism and heparin therapy.
    Morita S; Gebska MA; Kakkar AK; Scully MF
    Thromb Haemost; 2001 Aug; 86(2):616-22. PubMed ID: 11522012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.
    Spyropoulos AC; Turpie AG; Dunn AS; Spandorfer J; Douketis J; Jacobson A; Frost FJ;
    J Thromb Haemost; 2006 Jun; 4(6):1246-52. PubMed ID: 16706967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of venous thrombosis in cancer patients: practical aspects].
    Laza-Achille M; Desruennes E; Di Palma M
    Bull Cancer; 2006 Mar; 93(3):271-81. PubMed ID: 16567314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S; Welzel D; Hemker HC
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis.
    Cunningham RS
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S17-25; quiz S41-2. PubMed ID: 16638457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.
    Marchetti M; Vignoli A; Russo L; Balducci D; Pagnoncelli M; Barbui T; Falanga A
    Thromb Res; 2008; 121(5):637-45. PubMed ID: 17692905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer and thromboembolism: from biology to clinics.
    Castelli R; Porro F
    Minerva Med; 2006 Apr; 97(2):175-89. PubMed ID: 16760856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
    Creekmore FM; Oderda GM; Pendleton RC; Brixner DI
    Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of heparin to plasma proteins and endothelial surfaces is inhibited by covalent linkage to antithrombin.
    Chan AK; Paredes N; Thong B; Chindemi P; Paes B; Berry LR; Monagle P
    Thromb Haemost; 2004 May; 91(5):1009-18. PubMed ID: 15116263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
    Hull RD; Pineo GF
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of thromboembolism in hematologic malignancies.
    Chong BH; Lee SH
    Semin Thromb Hemost; 2007 Jun; 33(4):435-48. PubMed ID: 17525901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does antithrombotic therapy improve survival in cancer patients?
    Cunningham MS; Preston RJ; O'Donnell JS
    Blood Rev; 2009 May; 23(3):129-35. PubMed ID: 19046797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
    Burris HA
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S3-16; quiz S41-2. PubMed ID: 16638456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood.
    Hochart H; Jenkins PV; Preston RJ; Smith OP; White B; O'Donnell J
    Thromb Haemost; 2008 Mar; 99(3):570-5. PubMed ID: 18327406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.
    Mousa SA; Petersen LJ
    Thromb Haemost; 2009 Aug; 102(2):258-67. PubMed ID: 19652876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Do anticoagulants improve survival in patients with cancer?].
    Meyer G
    Pathol Biol (Paris); 2008 Jun; 56(4):233-8. PubMed ID: 18456421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.
    Nasser NJ; Sarig G; Brenner B; Nevo E; Goldshmidt O; Zcharia E; Li JP; Vlodavsky I
    J Thromb Haemost; 2006 Mar; 4(3):560-5. PubMed ID: 16460439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer.
    Lee AY
    Thromb Res; 2007; 120 Suppl 2():S121-7. PubMed ID: 18023705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.